GoAI
Get started
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares logo

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

CUPR

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$2.875

+$0.055 · +1.95%

Aug 21, 4:00 PM ET

CUPR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

22

Expensive

Momentum

49

Neutral

Sentiment

50

Mixed

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
SG
CEO
Yong Qi Quek
Listed since
Apr 10, 2025
Employees
10

Market position

Day range

Current $2.875

52-week range

Current $2.875

Open
$2.80
Previous close
$2.82
Volume
5.43K
0× average
Average volume
3.17M
Average daily volume
Market cap
7.71M USD
Beta
-0.38
Market reference 1
50-day average
$4.0697
-29.36% below average
200-day average
$3.6349
-20.91% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
7.89M SGD
EV / EBITDA
-1.73×
Earnings yield
-44.39%
Free cash flow yield
-87.31%

Profitability & efficiency

Return on equity
-92.44%
Return on assets
-54.95%
Return on invested capital
-82.48%

Financial health

Current ratio
2.35×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends980%-2782%-6545%-10307%Gross margin, FY2021: 39.41%Gross margin, FY2022: 35.30%Gross margin, FY2023: 36.32%Gross margin, FY2024: -6.26%Gross margin, FY2025: -1.29%Operating margin, FY2021: -944.81%Operating margin, FY2022: -2077.40%Operating margin, FY2023: -1060.13%Operating margin, FY2024: -3404.85%Operating margin, FY2025: -9154.62%Net margin, FY2021: -888.29%Net margin, FY2022: -1933.81%Net margin, FY2023: -1110.97%Net margin, FY2024: -3229.52%Net margin, FY2025: -9366.75%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 39.41%. Gross margin FY2022 35.30%. Gross margin FY2023 36.32%. Gross margin FY2024 -6.26%. Gross margin FY2025 -1.29%. Operating margin FY2021 -944.81%. Operating margin FY2022 -2077.40%. Operating margin FY2023 -1060.13%. Operating margin FY2024 -3404.85%. Operating margin FY2025 -9154.62%. Net margin FY2021 -888.29%. Net margin FY2022 -1933.81%. Net margin FY2023 -1110.97%. Net margin FY2024 -3229.52%. Net margin FY2025 -9366.75%.

Income trends

Revenue

49.89K SGD+3.26%

Operating income

−4.57M SGD-177.62%

Net income

−4.67M SGD-199.48%
Income trends across reported periods578.2K SGD−1.33M SGD−3.24M SGD−5.15M SGDRevenue, FY2021: 58.5K SGDRevenue, FY2022: 56.6K SGDRevenue, FY2023: 100.77K SGDRevenue, FY2024: 48.32K SGDRevenue, FY2025: 49.89K SGDOperating income, FY2021: −552.75K SGDOperating income, FY2022: −1.18M SGDOperating income, FY2023: −1.07M SGDOperating income, FY2024: −1.65M SGDOperating income, FY2025: −4.57M SGDNet income, FY2021: −519.69K SGDNet income, FY2022: −1.09M SGDNet income, FY2023: −1.12M SGDNet income, FY2024: −1.56M SGDNet income, FY2025: −4.67M SGDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 58.5K SGD. Revenue FY2022 56.6K SGD. Revenue FY2023 100.77K SGD. Revenue FY2024 48.32K SGD. Revenue FY2025 49.89K SGD. Operating income FY2021 −552.75K SGD. Operating income FY2022 −1.18M SGD. Operating income FY2023 −1.07M SGD. Operating income FY2024 −1.65M SGD. Operating income FY2025 −4.57M SGD. Net income FY2021 −519.69K SGD. Net income FY2022 −1.09M SGD. Net income FY2023 −1.12M SGD. Net income FY2024 −1.56M SGD. Net income FY2025 −4.67M SGD.
Metric (SGD)FY2025FY2024FY2023FY2022FY2021
Revenue49.89K SGD48.32K SGD100.77K SGD56.6K SGD58.5K SGD
Cost of goods sold50.54K SGD51.35K SGD64.17K SGD36.62K SGD35.45K SGD
Gross profit−645 SGD−3.02K SGD36.61K SGD19.98K SGD23.06K SGD
Research and development226.88K SGD241.36K SGD167.73K SGD292.88K SGD279.79K SGD
Selling, general, and administrative4.39M SGD1.27M SGD833.45K SGD830.36K SGD248.19K SGD
Operating expenses4.57M SGD1.64M SGD1.1M SGD1.2M SGD575.81K SGD
Interest income26.56K SGD————
Interest expense14.72K SGD37.21K SGD56.59K SGD2.02K SGD2.78K SGD
Depreciation and amortization36.52K SGD42.19K SGD35.06K SGD29.09K SGD27.46K SGD
Operating income−4.57M SGD−1.65M SGD−1.07M SGD−1.18M SGD−552.75K SGD
Net income−4.67M SGD−1.56M SGD−1.12M SGD−1.09M SGD−519.69K SGD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.84
FY2025
Latest fiscal-year revenue
49.89K SGD
FY2025 · +3.26% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.04-0.69-1.35-2FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend106.02K85.04K64.06K43.08KFY21FY22FY23FY24FY25

CUPR news

feeds.benzinga.com

Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending

Cuprina stock surged 112% after FDA clearance for MEDIFLY Maggots before falling sharply in after-hours trading.

Read source
globenewswire.com

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical…

Read source
globenewswire.com

Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements

SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility,…

Read source
globenewswire.com

Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility,…

Read source

Corporate actions

Corporate action history

Stock split

Effective May 27, 2026

1:8

CUPR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research CUPR

research.disclaimer